National Cancer Institute; Notice of Closed Meetings, 18465-18466 [2017-07842]
Download as PDF
18465
Federal Register / Vol. 82, No. 74 / Wednesday, April 19, 2017 / Notices
6. Investigate associations between
ZIKV infection in utero or in infancy
and hearing loss and other physical,
neurologic, and neurodevelopmental
outcomes at 6 months of age.
7. Estimate survival of infants born to
ZIKV infected mothers.
Secondary research questions we aim
to address with the ZEN Colombia study
are:
1. Identify risk factors for ZIKV
infection in pregnant women, partners
and infants. A spectrum of risk factors
will be explored, including mosquito
bites and mosquito bite preventive
measures, sexual transmission,
sociodemographic characteristics, and
medical risk factors. The results of this
analysis will provide information on the
reduction in risk associated with
adherence to recommended preventive
measures and risk factors for infection
in pregnant women.
2. Identify characteristics associated
with taking preventive measures
(mosquito bite prevention, sexual
transmission) against contracting Zika
virus among pregnant women and their
partners. The results of this analysis
will assist in targeting education or
intervention to individuals at greatest
risk for Zika infection.
3. Describe symptoms associated with
ZIKV and estimate the positive
predictive value of certain symptoms or
constellations of symptoms in pregnant
women, men, and infants to allow for
refinement of clinical diagnosis of ZIKV
infection in a setting in which testing
and/or results might not be readily
available.
4. Assess the duration of viremia
following ZIKV infection and
investigate risk factors (such as
sociodemographics, comorbidities, and
co-infections) associated with prolonged
viremia among pregnant women, men,
and infants with laboratory-confirmed
ZIKV infection in blood.
The project aims to enroll
approximately 5,000 women, 1,250 male
partners, and 4,500 newborns. Pregnant
women will be recruited in the first
trimester of pregnancy for study
enrollment, followed by assessments
during pregnancy (every other week
until 32 weeks gestation and monthly
thereafter), and at or within 72 hours of
delivery. At all visits, participants will
complete visit-specific questionnaires.
In addition to the questionnaires, at all
pregnancy and delivery visits,
participants will receive Colombian
national recommended clinical care and
provide samples for laboratory testing.
Male partners will be recruited
around the time of the pregnant
partners’ study enrollment, followed by
monthly visits until his pregnant
partner reaches the third trimester
(approximately 27 weeks gestation). If
the male partner contracts ZIKV during
this time, visits will occur every other
week until the partner has two negative
consecutive tests for ZIKV or the
pregnancy ends. At all study visits, male
partners will complete visit-specific
questionnaires and provide samples for
laboratory testing.
All newborns of mothers participating
in the study will be followed every
other week from birth to 6 months of
age. At all visits, infants will receive
national recommended clinical care (at
birth and clinic visits at 1, 2, 3, and 6
months), provide samples for laboratory
testing, and mothers will complete
study-specific questionnaires about
infant ZIKV symptoms. Infants will also
have cranial ultrasounds at birth, their
head circumference measured (birth, 72
hours, 1, 2, 3, and 6 months of age), and
enhanced hearing/vision tests at 1 and
6 months old. For mothers and their
infants, relevant information collected
as part of clinical care will be abstracted
from medical records. Study results will
be used to guide recommendations
made by both INS and CDC to prevent
ZIKV infection; to improve counseling
of patients about risks to themselves,
their pregnancies, their partners, and
their infants; and to help agencies
prepare to provide services to affected
children and families. Participation in
this study is voluntary. The total
estimated annualized burden hours are
19,415, and there are no costs to
participants other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Form name
Pregnant women .............................................
Pregnant women eligibility questionnaire ......
Pregnant women enrollment questionnaire ...
Adult symptom questionnaire .........................
Pregnant women follow-up questionnaire ......
Infant symptoms questionnaire ......................
Male partner eligibility questionnaire .............
Male enrollment questionnaire .......................
Adult symptom questionnaire .........................
Male partners ..................................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
jstallworth on DSK7TPTVN1PROD with NOTICES
[FR Doc. 2017–07879 Filed 4–18–17; 8:45 am]
15:06 Apr 18, 2017
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
BILLING CODE 4163–18–P
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Jkt 241001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
3,125
2,500
2,500
2,500
2,250
2,500
625
625
Number of
responses
per
respondent
Average
burden per
response
(in hours)
1
1
15
8
14
1
1
7
5/60
35/60
10/60
15/60
10/60
5/60
25/60
10/60
as amended. The grant applications/
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications/
contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; HPV
Review.
Date: May 10, 2017.
E:\FR\FM\19APN1.SGM
19APN1
jstallworth on DSK7TPTVN1PROD with NOTICES
18466
Federal Register / Vol. 82, No. 74 / Wednesday, April 19, 2017 / Notices
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W530, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Shamala K. Srinivas,
Ph.D., Associate Director, Office of Referral,
Review, and Program Coordination, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W530, Bethesda, MD 20892–9750,
240–276–6442, ss537t@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Immunotherapy Trials Network.
Date: May 18, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W102, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Shakeel Ahmad, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W102,
Bethesda, MD 20892–9750, 240–276–6349,
ahmads@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Technical
Evaluation Panel #1.
Date: May 23, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W260, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W260, Bethesda, MD 20892–
9750, 240–276–7684, nadeem.khan@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Technical
Evaluation Panel #2.
Date: May 24, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W260, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W260, Bethesda, MD 20892–
9750, 240–276–7684, nadeem.khan@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Drug Resistance 1.
Date: June 27–28, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
15:06 Apr 18, 2017
Jkt 241001
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Michael B. Small, Ph.D.,
Chief, Program and Review Extramural Staff
Training Office, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W412,
Bethesda, MD 20892–9750, 240–276–6438,
smallm@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Drug Resistance 2.
Date: June 27–28, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Wlodek Lopaczynski, MD,
Ph.D., Assistant Director, Office of the
Director, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W514, Bethesda, MD
20892–9750, 240–276–6340, lopacw@
mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
I—Transition to Independence.
Date: June 14–15, 2017.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crown Plaza National Airport, 1480
Crystal Drive, Arlington, VA 22202.
Contact Person: Delia Tang, MD, Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W602, Bethesda, MD 20892–9750,
240–276–6456, tangd@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 13, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–07842 Filed 4–18–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2017–0015]
Notice of Request for Revision to and
Extension of a Currently Approved
Information Collection for ChemicalTerrorism Vulnerability Information
National Protection and
Programs Directorate, DHS.
AGENCY:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
60-Day Notice and request for
comments; Revision of Information
Collection Request: 1670–0015.
ACTION:
The Department of Homeland
Security (DHS or the Department),
National Protection and Programs
Directorate (NPPD), Office of
Infrastructure Protection (IP),
Infrastructure Security Compliance
Division (ISCD), will submit the
following Information Collection
Request to the Office of Management
and Budget (OMB) for review and
clearance in accordance with the
Paperwork Reduction Act of 1995. DHS
proposes to remove five of the six
instruments previously approved to
support the Chemical-terrorism
Vulnerability Information (CVI) program
under the Chemical Facility Antiterrorism Standards (CFATS)
regulations, 6 CFR 27.400. DHS also
proposes to extend this collection with
revisions to reduce the estimated
burden for the remaining instrument in
this collection.
DATES: Comments are encouraged and
will be accepted until June 19, 2017.
This process is conducted in accordance
with 5 CFR 1320.8.
ADDRESSES: Interested persons are
invited to submit comments on the
proposed revision to, and extension of,
this approved information collection
through the Federal eRulemaking Portal
at https://www.regulations.gov. All
submissions received must include the
words ‘‘Department of Homeland
Security’’ and the docket number DHS–
2017–0015. Except as provided below,
comments received will be posted
without alteration at https://
www.regulations.gov, including any
personal information provided.
Comments that include trade secrets,
confidential commercial or financial
information, CVI,1 Sensitive Security
Information (SSI),2 or Protected Critical
Infrastructure Information (PCII) 3
should not be submitted to the public
regulatory docket. Please submit such
comments separately from other
comments in response to this notice.
Comments containing trade secrets,
confidential commercial or financial
information, CVI, SSI, or PCII should be
appropriately marked and packaged in
SUMMARY:
1 For more information about CVI see 6 CFR
27.400 and the CVI Procedural Manual at https://
www.dhs.gov/xlibrary/assets/chemsec_cvi_
proceduresmanual.pdf.
2 For more information about SSI see 49 CFR part
1520 and the SSI Program Web page at https://
www.tsa.gov.
3 For more information about PCII see 6 CFR part
29 and the PCII Program Web page at https://
www.dhs.gov/protected-critical-infrastructureinformation-pcii-program.
E:\FR\FM\19APN1.SGM
19APN1
Agencies
[Federal Register Volume 82, Number 74 (Wednesday, April 19, 2017)]
[Notices]
[Pages 18465-18466]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07842]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications/contract proposals and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications/contract
proposals, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; HPV Review.
Date: May 10, 2017.
[[Page 18466]]
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W530, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Shamala K. Srinivas, Ph.D., Associate Director,
Office of Referral, Review, and Program Coordination, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W530, Bethesda, MD 20892-9750, 240-276-6442,
ss537t@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cancer Immunotherapy Trials Network.
Date: May 18, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W102, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Shakeel Ahmad, Ph.D., Scientific Review Officer,
Research Programs Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W102, Bethesda, MD 20892-9750, 240-276-6349, ahmads@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Technical Evaluation Panel #1.
Date: May 23, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W260, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-276-7684,
nadeem.khan@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Technical Evaluation Panel #2.
Date: May 24, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W260, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-276-7684,
nadeem.khan@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cancer Drug Resistance 1.
Date: June 27-28, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Gaithersburg Marriott Washingtonian Center, 9751
Washingtonian Boulevard, Gaithersburg, MD 20878.
Contact Person: Michael B. Small, Ph.D., Chief, Program and
Review Extramural Staff Training Office, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W412, Bethesda, MD 20892-9750, 240-276-6438,
smallm@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cancer Drug Resistance 2.
Date: June 27-28, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Gaithersburg Marriott Washingtonian Center, 9751
Washingtonian Boulevard, Gaithersburg, MD 20878.
Contact Person: Wlodek Lopaczynski, MD, Ph.D., Assistant
Director, Office of the Director, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W514, Bethesda, MD 20892-9750, 240-276-6340, lopacw@mail.nih.gov.
Name of Committee: National Cancer Institute Initial Review
Group; Subcommittee I--Transition to Independence.
Date: June 14-15, 2017.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Crown Plaza National Airport, 1480 Crystal Drive,
Arlington, VA 22202.
Contact Person: Delia Tang, MD, Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W602, Bethesda, MD 20892-9750, 240-276-6456,
tangd@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 13, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-07842 Filed 4-18-17; 8:45 am]
BILLING CODE 4140-01-P